Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kabi Stretches Adalimumab Presence To Nine Countries

Four Further Country Launches During Third Quarter

Executive Summary

Having started to roll out its Idacio adalimumab biosimilar in Europe earlier this year, Fresenius Kabi is now marketing the Humira rival in nine countries.

You may also be interested in...

Emerging Markets Help Fresenius Kabi Offset US Pressures

Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.

Kabi Commits To Biosimilars Development

Fresenius Kabi says a research and development center that it has opened in Switzerland demonstrates its commitment to its biosimilars pipeline.

Fresenius Tempers Expectations For Adalimumab Biosimilar

As a late entrant to the European adalimumab market, Fresenius is cooling expectations for sales of its Idacio biosimilar while it continues work on late-stage candidates pegfilgrastim and tocilizumab.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts